相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage
Xuening Wang et al.
EXPERIMENTAL CELL RESEARCH (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
Ekta Agarwal et al.
BMC CANCER (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Robert M. Campbell et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
V. Munugalavadla et al.
ONCOGENE (2014)
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
D. W. Bowles et al.
BRITISH JOURNAL OF CANCER (2013)
Molecular and cellular pathogenesis of melanoma initiation and progression
Tarik Regad
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Therapeutic targeting of c-KIT in cancer
Leonie K. Ashman et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
ERK5 and its role in tumour development
Pamela A. Lochhead et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
Clare Davies et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Mechanisms of FGFR-mediated carcinogenesis
Imran Ahmad et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Nancy U. Lin et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
C. Cauchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
mTOR inhibitors in cancer therapy
Yekaterina Y. Zaytseva et al.
CANCER LETTERS (2012)
Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
Paul G. Richardson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
Sara Previdi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
STEM CELL FACTOR RECEPTOR/c-KIT: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
Johan Lennartsson et al.
PHYSIOLOGICAL REVIEWS (2012)
PI3K-PKB/Akt Pathway
Brian A. Hemmings et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
MAP Kinase Pathways
Deborah K. Morrison
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Signal Transduction by Vascular Endothelial Growth Factor Receptors
Sina Koch et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Blocking the mTOR pathway: a drug discovery perspective
Carlos Garcia-Echeverria
BIOCHEMICAL SOCIETY TRANSACTIONS (2011)
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Kenji Takeuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Ted L. Underiner et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Mechanisms and functions of p38 MAPK signalling
Ana Cuadrado et al.
BIOCHEMICAL JOURNAL (2010)
New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
Federica Toffalini et al.
BLOOD (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
8p11 myeloproliferative syndrome: a review
Courtney C. Jackson et al.
HUMAN PATHOLOGY (2010)
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma
Helena Nord et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
De-regulated FGF receptors as therapeutic targets in cancer
Victoria Knights et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
Kimmo J. Hatanpaa et al.
NEOPLASIA (2010)
Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase
Mingqiang Ren et al.
BLOOD (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Molecular determinants of tumor recurrence in the urinary bladder
Liang Cheng et al.
FUTURE ONCOLOGY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer
Qingshan Chang et al.
JOURNAL OF HEPATOLOGY (2009)
FGFR3 mutations in prostate cancer: association with low-grade tumors
Silvia Hernandez et al.
MODERN PATHOLOGY (2009)
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Sean G. Buchanan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip
Annie Chou et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Lindsay Marek et al.
MOLECULAR PHARMACOLOGY (2009)
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
M. S. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival
Kaiko Kunii et al.
CANCER RESEARCH (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer
Isabelle Bernard-Pierrot et al.
CANCER RESEARCH (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung
Donatella Malanga et al.
CELL CYCLE (2008)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2008)
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
Lijian Hui et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
K. A. Hahn et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Targeting EGFR in colorectal cancer
Wells A. Messersmith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Mitogen-activated protein (MAP) Kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer
Tarek Boutros et al.
PHARMACOLOGICAL REVIEWS (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer
Kerstin B. Meyer et al.
PLOS BIOLOGY (2008)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
BRAF mutation in papillary thyroid cancer:: Pathogenic role, molecular bases, and clinical implications
Mingzhao Xing
ENDOCRINE REVIEWS (2007)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Amy L. Howes et al.
MOLECULAR CANCER THERAPEUTICS (2007)
High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications
Kylie L. Gorringe et al.
CLINICAL CANCER RESEARCH (2007)
P38 MAP-Kinases pathway regulation, function and role in human diseases
Ana Cuenda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
David J. Hunter et al.
NATURE GENETICS (2007)
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
Val R. Adams et al.
CLINICAL THERAPEUTICS (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Receptor tyrosine kinases: mechanisms of activation and signaling
Stevan R. Hubbard et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
A genomic analysis of adult T-cell leukemia
Y. L. Choi et al.
ONCOGENE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Recurrent FGFR 1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)
Kolja Freier et al.
ORAL ONCOLOGY (2007)
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: A basis for novel approaches and individualization of treatment
Stefan Sleijfer et al.
ONCOLOGIST (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas
Marjut Puputti et al.
MOLECULAR CANCER RESEARCH (2006)
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Koei Chin et al.
CANCER CELL (2006)
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
Jorge Sergio Reis-Filho et al.
CLINICAL CANCER RESEARCH (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
Anne Letessier et al.
BMC CANCER (2006)
Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation
Toshiharu Sakurai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting the c-Met signaling pathway in cancer
Benedetta Peruzzi et al.
CLINICAL CANCER RESEARCH (2006)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Filippo Montemurro et al.
ONCOLOGIST (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma
CT Miller et al.
ONCOGENE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Regulation of cellular functions by the ERK5 signalling pathway
X Wang et al.
CELLULAR SIGNALLING (2006)
Comprehensive profiling of 8p11-12 amplification in breast cancer
W Gelsi-Boyer et al.
MOLECULAR CANCER RESEARCH (2005)
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
V Rand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis
M Hayashi et al.
CANCER RESEARCH (2005)
Somatic mutations of the protein kinase gene family in human lung cancer
H Davies et al.
CANCER RESEARCH (2005)
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation
LA McDermott et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes
MJ Garcia et al.
ONCOGENE (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
E Wardelmann et al.
LANCET ONCOLOGY (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma
JMG Pedrero et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
E Lengyel et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway
X Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Regulation of anoikis by Cdc42 and Rac1
TL Cheng et al.
EXPERIMENTAL CELL RESEARCH (2004)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
D Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
S Roumiantsev et al.
CANCER CELL (2004)
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation
K Sabapathy et al.
MOLECULAR CELL (2004)
Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas
M Hecht et al.
CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Juxtamembrane autoinhibition in receptor tyrosine kinases
SR Hubbard
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its comolex with the microbial alkaloid K-252a
N Schiering et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis
H Arai et al.
CANCER GENETICS AND CYTOGENETICS (2003)
Regulation of Raf through phosphorylation and N terminus-C terminus interaction
HR Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion
PB Mehta et al.
ONCOGENE (2003)
c-Met: Structure, functions and potential for therapeutic inhibition
PC Ma et al.
CANCER AND METASTASIS REVIEWS (2003)
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis
JA Nagy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
BWG van Rhijn et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2002)
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma
J Woenckhaus et al.
JOURNAL OF PATHOLOGY (2002)
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases
JA McKay et al.
EUROPEAN JOURNAL OF CANCER (2002)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors
JM Zhao et al.
GENES CHROMOSOMES & CANCER (2002)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
A Demiroglu et al.
BLOOD (2001)
Integrin β1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity
NA Bhowmick et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
M Chesi et al.
BLOOD (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
KA Furge et al.
ONCOGENE (2000)
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
MJ Karkkainen et al.
ONCOGENE (2000)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features
JS Smith et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2000)
分享论文
